Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants

Wan-Zhen Li,Hai-Lan Wu,Yuan-Cheng Chen,Bei-Ning Guo,Xiao-Fen Liu,Yu Wang,Ju-Fang Wu,Jing Zhang
DOI: https://doi.org/10.21037/atm-21-588
IF: 3.616
2021-06-01
Annals of Translational Medicine
Abstract:BACKGROUND: Ceftobiprole is a novel β-lactam cephalosporin with activity against Gram-positive and -negative bacteria. The aim of the present study was to investigate the pharmacokinetics (PK), pharmacokinetics/pharmacodynamics (PK/PD), safety and tolerance of ceftobiprole in Chinese participants, to evaluate this dosage regimen for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) in China.METHODS: The use of ceftobiprole was investigated in a single-center, open-label, single- and multiple-dose study using 12 healthy Chinese participants (6 males and 6 females). Ceftobiprole plasma and urine concentrations were analyzed using a validated liquid chromatography-tandem mass spectrometry assay. The PK/PD characteristics of 500 mg ceftobiprole every 8 h at 1.5-, 2-, 3-, or 4-h infusion time were analyzed by Monte Carlo simulations (MCS).RESULTS: The maximum plasma concentration of ceftobiprole was observed 2 h after dosage; its terminal half-life was about 3 h. Ceftobiprole was predominantly eliminated in urine, and the cumulative excretion in 24 h was &gt;90%. There was no accumulation after multiple dosing. Both single and multiple doses were well tolerated, with no severe or serious adverse events (AEs). PK/PD analysis indicated that <i>Staphylococcus pneumoniae</i> (<i>S. pneumoniae</i>) and <i>Staphylococcus aureus</i> (<i>S. aureus</i>) were sensitive to ceftobiprole. About half of extended-spectrum β-lactamase (ESBL) non-producing <i>Enterobacteriaceae</i> are sensitive to ceftobiprole, according to PK/PD results of ceftobiprole. For <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>), no regimen was found to be effective against strains.CONCLUSIONS: The PK/PD results indicated that 500 mg ceftobiprole every 8 h at 2-h infusion time is expected to achieve good microbiological efficacy in the treatment of CAP and HAP in China.
oncology,medicine, research & experimental
What problem does this paper attempt to address?